Szupera Zoltán
Neurológiai Osztály, Szombathely.
Ideggyogy Sz. 2007 Jan 20;60(1-2):4-13.
It is well known that alterations in sexual functions occur more frequently in men with epilepsy than in general population. The results of the epidemiological studies are considerably diverge from one another (3-61%), so the exact value of the incidence is not known. The most common form of sexual dysfunctions is the hyposexuality, determined as a overall reduction in sexual interest, awareness, and activity. Sexual dysfunction, as a disorder is often multifactorial, but the role of medical factors can be the most important in the development. The endocrinological disturbances occurring in epilepsy are mainly caused by the pharmacokinetic interactions among the antiepileptic medication. The enzyme inductor drugs decrease the level of free testosterone, dihydrotestosterone, follicle stimulating hormone, and luteinizing hormone, and increase the sex-hormone-binding globulin and estradiol levels. In valproate treated men significantly lower follicle stimulating hormone and luteinizing hormone concentrations, and free/total carnitine ratio, and higher dehydroepiandrosterone concentration can be detected. The enzyme inductor antiepileptic drugs can decrease the biologically active testosterone level by stimulating the aromatase and the hepatic cytochrome P450 enzymes, which can result in the development of sexual dysfunctions. Hormonal changes resulting in the alteration of the androgen synthesis and gonadotropin levels may contribute to the sexual dysfunction observed in valproate treated epileptic patients. If the role of the antiepileptic medication can be proven in the development of the sexual dysfunctions, changing in the antiepileptic drug therapy is recommended. According to evidences, the usage of oxcarbazepine and lamotrigine is not associated with changes in hormonal levels, and does not lead to alterations in sexual functions. In case of sexual dysfunctions switching from carbamazepine to oxcarbazepine, levetiracetam, or gabapentin is recommended in patients with partial epilepsy, and from valproate to lamotrigine or levetiracetam in patients with idiopathic generalized epilepsy. Enforcement of the primary prevention in the treatment of men with epilepsy is an important task of the future.
众所周知,癫痫男性比普通人群更频繁地出现性功能改变。流行病学研究结果差异很大(3%-61%),因此发病率的确切数值尚不清楚。性功能障碍最常见的形式是性欲减退,表现为性兴趣、意识和活动的全面降低。性功能障碍作为一种病症通常是多因素的,但医学因素在其发生过程中可能起最重要的作用。癫痫中发生的内分泌紊乱主要由抗癫痫药物之间的药代动力学相互作用引起。酶诱导剂药物会降低游离睾酮、双氢睾酮、促卵泡激素和促黄体生成素的水平,并提高性激素结合球蛋白和雌二醇水平。在丙戊酸盐治疗的男性中,可检测到促卵泡激素和促黄体生成素浓度以及游离/总肉碱比值显著降低,而脱氢表雄酮浓度升高。酶诱导剂抗癫痫药物可通过刺激芳香化酶和肝细胞色素P450酶来降低生物活性睾酮水平,这可能导致性功能障碍的发生。导致雄激素合成和促性腺激素水平改变的激素变化可能促成了丙戊酸盐治疗的癫痫患者中观察到的性功能障碍。如果抗癫痫药物在性功能障碍发生过程中的作用能够得到证实,建议改变抗癫痫药物治疗方案。根据证据,使用奥卡西平和拉莫三嗪与激素水平变化无关,也不会导致性功能改变。对于部分性癫痫患者,若出现性功能障碍,建议从卡马西平换用奥卡西平、左乙拉西坦或加巴喷丁;对于特发性全身性癫痫患者,建议从丙戊酸盐换用拉莫三嗪或左乙拉西坦。在癫痫男性患者的治疗中加强一级预防是未来的一项重要任务。